VCP
APLS

Verus Capital Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Verus Capital Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$71K Hold
2,655
– – 0.02% 396
2019
Q4 		$81K Buy
+2,655
New +$73.5K 0.03% 442

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Verus Capital Partners's APLS Position: Q1 2020 in Review

Verus Capital Partners held its Apellis Pharmaceuticals (APLS) position steady in Q1 2020 at 2,655 shares worth $71K. The position accounts for 0.02% of the portfolio, ranked #396.

Verus Capital Partners first reported a position in APLS in Q4 2019 and has held it in 2 quarters since. The position peaked at $81K in Q4 2019. 143 funds tracked by Wall St. Rank hold APLS as of Q1 2020.

  • Verus Capital Partners held 2,655 shares of Apellis Pharmaceuticals worth $71K as of Q1 2020.
  • Verus Capital Partners left its Apellis Pharmaceuticals share count unchanged in Q1 2020.
  • Apellis Pharmaceuticals made up 0.02% of Verus Capital Partners's portfolio in Q1 2020, its #396 holding.
  • Verus Capital Partners first reported a position in Apellis Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Apellis Pharmaceuticals position peaked at $81K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.